LGD 6972

Drug Profile

LGD 6972

Alternative Names: Compound G; Compound H; Cpd G; Cpd H; GCGR Antagonist Program - Ligand Pharmaceuticals; GRA; LGD-6972; LGD-6972 sodium salt; MB-11262

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 27 Feb 2017 Ligand Pharmaceuticals completes enrolment in its phase II trial for Type 2 diabetes in USA
  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Phase-II clinical trials in Type-2 diabetes mellitus (Treatment-experienced) in USA (PO) (NCT02851849)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top